CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been assigned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $71.60.

Several equities research analysts have recently weighed in on the company. JMP Securities reissued a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Chardan Capital reissued a “buy” rating and set a $82.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, August 5th. Wall Street Zen raised CRISPR Therapeutics to a “sell” rating in a research report on Friday, May 16th. Bank of America cut their target price on CRISPR Therapeutics from $79.00 to $78.00 and set a “buy” rating on the stock in a research report on Tuesday, July 22nd. Finally, HC Wainwright lifted their price target on CRISPR Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 7th.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider directly owned 6,068 shares in the company, valued at approximately $218,083.92. This trade represents a 39.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Simeon George bought 989,812 shares of the stock in a transaction on Wednesday, July 16th. The stock was bought at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the purchase, the director directly owned 1,730,179 shares in the company, valued at approximately $90,021,213.37. The trade was a 133.69% increase in their position. The disclosure for this purchase can be found here. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. ARK Investment Management LLC grew its stake in shares of CRISPR Therapeutics by 13.3% in the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company’s stock valued at $345,929,000 after purchasing an additional 1,192,336 shares during the last quarter. Capital International Investors boosted its stake in shares of CRISPR Therapeutics by 10.3% in the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock valued at $344,145,000 after buying an additional 816,789 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of CRISPR Therapeutics by 39.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after buying an additional 1,074,238 shares in the last quarter. State Street Corp boosted its stake in shares of CRISPR Therapeutics by 35.6% in the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after buying an additional 859,334 shares in the last quarter. Finally, Orbis Allan Gray Ltd boosted its stake in shares of CRISPR Therapeutics by 76.9% in the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock valued at $134,467,000 after buying an additional 1,201,600 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

CRSP stock opened at $59.73 on Friday. CRISPR Therapeutics has a 1 year low of $30.04 and a 1 year high of $71.13. The firm has a market capitalization of $5.43 billion, a P/E ratio of -11.00 and a beta of 1.80. The business’s 50-day moving average is $53.49 and its two-hundred day moving average is $44.44.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%. The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $6.44 million. During the same quarter last year, the company earned ($1.49) EPS. The business’s quarterly revenue was up 72.5% on a year-over-year basis. On average, analysts expect that CRISPR Therapeutics will post -5.16 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.